AI
DRUG

AdvisorShares Investments’s Bright Minds Biosciences DRUG Stock Holding History

AdvisorShares Investments’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$920K Buy
12,613
+2,669
+27% +$215K 0.17% 87
2025
Q4 		$776K Sell
9,944
-3,765
-27% -$252K 0.13% 95
2025
Q3 		$832K Sell
13,709
-772
-5% -$30K 0.14% 87
2025
Q2 		$378K Buy
14,481
+3,200
+28% +$95.9K 0.07% 195
2025
Q1 		$407K Buy
11,281
+8,206
+267% +$300K 0.08% 173
2024
Q4 		$111K Sell
3,075
-179,345
-98% -$6.31M 0.02% 243
2024
Q3 		$219K Buy
182,420
+1,428
+0.8% +$1.61K 0.04% 213
2024
Q2 		$190K Buy
180,992
+4,954
+3% +$5.59K 0.03% 224
2024
Q1 		$211K Sell
176,038
-12,081
-6% -$21.2K 0.04% 223
2023
Q4 		$273K Buy
188,119
+20,189
+12% +$28.8K 0.06% 217
2023
Q3 		$267K Buy
167,930
+64,867
+63% +$173K 0.07% 181
2023
Q2 		$294K Buy
103,063
+13,232
+15% +$37.2K 0.08% 180
2023
Q1 		$198K Buy
89,831
+26,858
+43% +$89K 0.06% 195
2022
Q4 		$233K Buy
62,973
+5,917
+10% +$29.3K 0.07% 211
2022
Q3 		$351K Sell
57,056
-859
-1% -$5.57K 0.09% 201
2022
Q2 		$237K Buy
57,915
+16,572
+40% +$87.7K 0.07% 136
2022
Q1 		$314K Buy
41,343
+22,155
+115% +$248K 0.05% 127
2021
Q4 		$304K Buy
+19,188
New +$427K 0.04% 130

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AdvisorShares Investments's DRUG Position: Q1 2026 in Review

AdvisorShares Investments increased its Bright Minds Biosciences (DRUG) stake by 27% in Q1 2026, buying an estimated $215K and bringing the position to 12,613 shares worth $920K. The position accounts for 0.17% of the portfolio, ranked #87.

AdvisorShares Investments first reported a position in DRUG in Q4 2021 and has held it in 18 quarters since. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • AdvisorShares Investments held 12,613 shares of Bright Minds Biosciences worth $920K as of Q1 2026.
  • AdvisorShares Investments bought 2,669 Bright Minds Biosciences shares in Q1 2026, an estimated $215K.
  • Bright Minds Biosciences made up 0.17% of AdvisorShares Investments's portfolio in Q1 2026, its #87 holding.
  • AdvisorShares Investments first reported a position in Bright Minds Biosciences in Q4 2021 and has held it in 18 quarters since.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on AdvisorShares Investments's 13F filing for Q1 2026, filed 28 Apr 2026.